Stock Events

Stock Events

Insulet 

€143.55
138
+€7.85+5.78% Thursday 15:30

Statistics

Day High
142.1
Day Low
141.85
52W High
143.55
52W Low
124.85
Volume
19
Avg. Volume
-
Mkt Cap
9.94B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q1 2026
Next
1.02
1.1
1.19
1.27
Expected EPS
1.2675180298
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GOV.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tandem Diabetes Care
TNDM
Mkt Cap1.11B
Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.
Medtronic
MDT
Mkt Cap106.49B
Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.
Dexcom
DXCM
Mkt Cap27.49B
DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.
Abbott Laboratories
ABT
Mkt Cap166.17B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.
Insulet
PODD
Mkt Cap11.39B
Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.
Senseonics
SENS
Mkt Cap286.07M
Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.
Novo Nordisk
NVO
Mkt Cap223.19B
Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.
Sanofi
SNY
Mkt Cap103.32B
Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.
Mannkind
MNKD
Mkt Cap1.4B
MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Show more...
CEO
ISIN
US45784P1012
WKN
000A0MQX8

Listings

MI
IT
1PODD.MI
LSE
GB
0ADR.LSE
XETRA
DE
GOV.XETRA
STU
DE
GOV.STU

0 Comments

Share your thoughts

FAQ

What is Insulet stock price today?▼
The current price of GOV.XETRA is €143.55 EUR — it has increased by +5.78% in the past 24 hours. Watch Insulet stock price performance more closely on the chart.
What is Insulet stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Insulet stocks are traded under the ticker GOV.XETRA.
What is Insulet market cap?▼
Today Insulet has the market capitalization of 9.94B
When is the next Insulet earnings date?▼
Insulet is going to release the next earnings report on August 05, 2026.
What were Insulet earnings last quarter?▼
GOV.XETRA earnings for the last quarter are 1.21 EUR per share, whereas the estimation was 1.02 EUR resulting in a +18.46% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Insulet located?▼
Insulet operates in the Other sector.
When did Insulet complete a stock split?▼
Insulet has not had any recent stock splits.